

Date of preparation: 30 March 2026

Issuer's abbreviated name: SYN2BIO SA

Current report: 2/2026 ESPI

Subject: Fulfilment of the condition for the Issuer's shares to be admitted to trading

Legal basis: Article 56 section 1, subsection 2 of the Polish Act on Public Offering – current and periodic information

Body of the report:

Time of publication: 08:06 a.m.

The Management Board of Syn2bio SA with its registered office in Warsaw ("Issuer") hereby informs that due to the registration on 27 March 2026 by the District Court for the Capital City of Warsaw in Warsaw, XIII Commercial Division of the National Court Register, of an amendment to the Issuer's Articles of Association concerning an increase in the share capital in connection with the division of Synektik SA, the condition for the admission of all the Issuer's shares to trading on the regulated market has been fulfilled.

Pursuant to Resolution No. 406/2026 of 24 March 2026 of the Management Board of the Warsaw Stock Exchange SA on the admission to trading on the WSE Main Market of series A and B ordinary bearer shares of SYN2BIO SA, all the Issuer's shares have been admitted to trading on the main market.

Representatives of the Issuer:

Cezary Kozanecki - President of the Management Board